CMPSCOMPASS Pathways plc

Nasdaq compasspathways.com


$ 6.94 $ -0.12 (-1.7 %)    

Tuesday, 20-Aug-2024 15:59:32 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 6.93
$ 6.97
$ 6.93 x 200
$ 6.95 x 200
$ 6.91 - $ 7.03
$ 5.01 - $ 12.75
218,129
na
473.81M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-compass-pathways-lowers-price-target-to-48

Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target fr...

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 rbc-capital-initiates-coverage-on-compass-pathways-with-outperform-rating-announces-price-target-of-23

RBC Capital analyst Leonid Timashev initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Outperform rating and announ...

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

 cantor-fitzgerald-reiterates-overweight-on-compass-pathways

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

Core News & Articles

https://www.marijuanamoment.net/top-federal-drug-official-says-theres-tremendous-excitement-around-psych

 hc-wainwright--co-reiterates-buy-on-compass-pathways-maintains-120-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...

 compass-pathways-reports-q1-cash-and-cash-equivalents-of-2629m

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The ...

 compass-pathways-announced-topline-results-from-an-open-label-phase-2-study-of-comp360-psilocybin-treatment-for-post-traumatic-stress-disorder-the-study-met-its-primary-safety-endpoint-and-available-secondary-efficacy-endpoints

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clin...

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION